Comparative Evaluation of Isavuconazonium Sulfate

Total Page:16

File Type:pdf, Size:1020Kb

Comparative Evaluation of Isavuconazonium Sulfate Van Matre et al. Ann Clin Microbiol Antimicrob (2019) 18:13 https://doi.org/10.1186/s12941-019-0311-3 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center Edward T. Van Matre1 , Shelby L. Evans2, Scott W. Mueller3, Robert MacLaren3, Douglas N. Fish3 and Tyree H. Kiser3,4* Abstract Background: Invasive fungal infections are a major cause of morbidity and mortality. Newer antifungals may provide similar efcacy with improved safety compared to older more established treatments. This study aimed to compare clinically relevant safety and efcacy outcomes in real world patients treated with isavuconazole, voriconazole, or posaconazole. Methods: This single center retrospective matched cohort study evaluated adults between January 2015 and Decem- ber 2017. The primary outcome was a composite safety analysis of antifungal related QTc prolongation, elevated liver function tests (> 5 times ULN), or any documented adverse drug event. Key secondary outcomes included: individual safety events, 30-day readmissions, magnitude of drug interactions with immunosuppressive therapy, and overall cost. Results: A total of 100 patients were included: 34 patients in the voriconazole group and 33 patients within each of the isavuconazole and posaconazole groups. The composite safety outcome occurred in 40% of the total cohort and was diferent between isavuconazole (24.2%), voriconazole (55.9%), and posaconazole (39.4%; p 0.028). Change in QTc (p < 0.01) and magnitude of immunosuppression dose reduction (p 0.029) were diferent between= the three groups. No diferences in mortality, length of stay, readmission, or infection= recurrence were observed between groups (p > 0.05 for all). The overall medication cost, when including therapeutic drug monitoring, was not diferent between treatments (p 0.36). = Conclusions: Patients treated with isavuconazole resulted in fewer composite safety outcomes, driven by decreased incidence of QTc prolongation, compared to patients treated with voriconazole or posaconazole. Overall drug cost was not signifcantly diferent between the treatment therapy options. Keywords: Isavuconazole, Voriconazole, Posaconazole, Mycoses, Aspergillus Background data, invasive aspergillosis is the most common type of Invasive fungal infections are a major cause of morbid- fungal infection in stem cell transplant patients and the ity and mortality among patients, particularly those with second most common fungal infection in solid organ a compromised immune system. According to published transplant patients, with an incidence of 19% during a surveillance period from 2001 to 2006 [1, 2]. Te 1-year survival rate associated with invasive aspergillosis infec- *Correspondence: [email protected] 4 Department of Clinical Pharmacy, University of Colorado Anschutz tions is roughly 59% in solid organ transplant patients Medical Campus, 12850 East Montview Blvd, mailstop C238, Aurora, CO and 25% among stem cell transplant patients [1]. Mucor- 80045, USA mycosis was identifed as the third most common cause Full list of author information is available at the end of the article © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/ publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Van Matre et al. Ann Clin Microbiol Antimicrob (2019) 18:13 Page 2 of 7 of fungal infections in stem cell transplant patients and prisoners, pregnancy) as defned by institutional review while rarer than invasive aspergillosis infections, the all- board. cause mortality rate in these patients is estimated at 54% [3]. Primary end point Invasive mucormycosis and aspergillosis are difcult Te primary outcome evaluated was a composite safety infections to treat and the cost of therapy adds additional outcome (occurrence of any of the following safety events burden to the United States healthcare system. In 2009, it after the initiation of an antifungal): QTc prolongation was estimated that each case of mucormycosis results in (> 470 ms for females and > 450 ms for males), liver func- an average cost of $97,743, totaling over $50 million per tion tests fve times the upper limit of normal (ALT > 260 year [4]. Monitoring of therapeutic drug levels for certain units/L and AST > 195 units/L), or any documented medications further adds to this already high treatment antifungal treatment related adverse event based on pri- cost. Current frst-line treatment for invasive aspergillo- mary team documentation within the electronic medical sis, based on the Infectious Disease Society of America record. guidelines, is voriconazole. Te primary alternative ther- apy options are isavuconazole and liposomal or lipid for- Secondary end points mulations of amphotericin B. Posaconazole is a third-line Te secondary outcomes evaluated were the individual agent for patients with clinical failure or adverse events. components of the composite outcome, percent change Echinocandin therapy may be considered as combination in QTc length from baseline; percent change in calcineu- therapy with a triazole or as salvage therapy [5]. Current rin inhibitor serum concentration from baseline using frst-line treatment for invasive mucormycosis is ampho- the following equation: tericin B, in patients who can tolerate the nephrotoxic Baseline total daily dose − Adjusted total daily dose side efects. Other options include posaconazole and Baseline steady state serum concentration Adjusted steady state serum concentration × 100 Baseline total daily dose isavuconazonium sulfate (isavuconazole) for alternate or Baseline steady state serum concentration step-down therapy [6]. total cost of inpatient antifungal therapy per day, utilizing In recent clinical trials isavuconazole showed similar average wholesale price (AWP) and hospital cost for ther- efcacy and improved safety compared to voriconazole apeutic drug monitoring; all-cause in-hospital mortality; for the treatment of invasive molds and mucormycosis hospital length of stay; and intensive care unit length of [7, 8]. Te use of isavuconazole in a variety of clinical stay. settings is expanding. Tis study aimed to evaluate the utilization of isavuconazole at a single center academic Statistical analysis medical center, and to comparatively evaluate efective- In order to minimize selection bias and ensure simi- ness, safety, and cost between isavuconazole, voricona- lar comparator groups, patients were grouped based on zole, and posaconazole. indication for antifungal use, concomitant disease pro- cesses, and baseline demographics (e.g. age, neutropenia, Methods renal dysfunction, and hepatic dysfunction). Similar fre- Study design quency of each group were included. Based on previously reported adverse event rates of approximately 60% [7], Tis was a retrospective cohort study conducted at 30 patients were needed in each group to detect a 30% the University of Colorado Hospital between January diference in the primary outcome between groups with 2015 and December 2017. Te study was reviewed and 80% power and an alpha of 5%. approved by the Colorado Multiple Institutional Review Over the entire study period 35 patients received isa- Board. Patients were identifed through the University vuconazole, 53 patients received posaconazole, and 115 of Colorado Hospital’s electronic medical records using patients received voriconazole. Given the disparity of use medication usage reports. Study data were collected and between the groups over the study period patients were managed using REDCap electronic data capture tools matched to provide a balanced comparative evaluation. hosted at the University of Colorado Anschutz Medi- Patients were primarily matched on indication of use cal Campus [9]. Patients were included within the study (treatment vs prophylaxis), followed by admission diag- if they were 18 years of age and received isavucona- ≥ nosis and treatment month. Te isavuconazole treatment zonium sulfate (isavuconazole), voriconazole, or posa- group was used as the reference for patient matching. conazole for active treatment of confrmed or suspected Categorical data were compared utilizing Chi squared fungal infection as part of routine clinical care. Patients test, if statistical signifcance was found pairwise compar- were excluded if they were vulnerable subjects (e.g. isons were performed between the groups. Continuous Van Matre et al. Ann Clin Microbiol Antimicrob (2019) 18:13 Page 3 of 7 normally distributed data were compared utilizing and posaconazole groups respectively. Of the 100 analysis of variance test followed by pairwise t-test, and patients included within the study a majority were male non-normally distributed data were compared utilizing (54%) with a mean age of 55.9 years of age and a major- Kruskal–Wallis test followed by pairwise Mann–Whitney ity of patients (62%) were admitted to UCH with a pri- U tests. All tests were two sided with an α level of 5% and mary oncologic diagnosis.
Recommended publications
  • Systemic Antifungal Drug Use in Belgium—
    Received: 7 October 2018 | Revised: 28 March 2019 | Accepted: 14 March 2019 DOI: 10.1111/myc.12912 ORIGINAL ARTICLE Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe Berdieke Goemaere1 | Katrien Lagrou2,3* | Isabel Spriet4,5 | Marijke Hendrickx1 | Eline Vandael6 | Pierre Becker1 | Boudewijn Catry6,7 1BCCM/IHEM Fungal Collection, Service of Mycology and Aerobiology, Sciensano, Summary Brussels, Belgium Background: Reports on the consumption of systemic antifungal drugs on a national 2 Department of Microbiology and level are scarce although of high interest to compare trends and the associated epi- Immunology, KU Leuven, Leuven, Belgium 3Clinical Department of Laboratory demiology in other countries and to assess the need for antifungal stewardship Medicine, National Reference Centre for programmes. Mycosis, University Hospitals Leuven, Leuven, Belgium Objectives: To estimate patterns of Belgian inpatient and outpatient antifungal use 4Department of Pharmaceutical and and provide reference data for other countries. Pharmacological Sciences, KU Leuven, Methods: Consumption records of antifungals were collected in Belgian hospitals Leuven, Belgium between 2003 and 2016. Primary healthcare data were available for the azoles for 5Pharmacy Department, University Hospitals Leuven, Leuven, Belgium the period 2010-2016. 6 Healthcare‐Associated Infections and Results: The majority of the antifungal consumption resulted from prescriptions of Antimicrobial Resistance, Sciensano, Brussels, Belgium fluconazole and itraconazole in the ambulatory care while hospitals were responsible 7Faculty of Medicine, Université Libre de for only 6.4% of the total national consumption and echinocandin use was limited. Bruxelles (ULB), Brussels, Belgium The annual average antifungal consumption in hospitals decreased significantly by Correspondence nearly 25% between 2003 and 2016, due to a decrease solely in non-university hos- Berdieke Goemaere, Sciensano, Mycology pitals.
    [Show full text]
  • Antifungals, Oral
    Antifungals, Oral Therapeutic Class Review (TCR) July 13, 2018 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. July 2018 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2018 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer FDA-Approved Indication(s) for oral use clotrimazole generic .
    [Show full text]
  • Structural Diversity in Echinocandin Biosynthesis: the Impact of Oxidation Steps and Approaches Toward an Evolutionary Explanation
    Z. Naturforsch. 2017; 72(1-2)c: 1–20 Wolfgang Hüttel* Structural diversity in echinocandin biosynthesis: the impact of oxidation steps and approaches toward an evolutionary explanation DOI 10.1515/znc-2016-0156 can be well applied to parts of the pathway; however, thus Received July 29, 2016; revised July 29, 2016; accepted August 28, far, there is no comprehensive theory that could explain 2016 the entire biosynthesis. Abstract: Echinocandins are an important group of cyclic Keywords: antifungals; gene clusters; metabolic diversity; non-ribosomal peptides with strong antifungal activ- non-ribosomal peptide biosynthesis; secondary meta- ity produced by filamentous fungi from Aspergillaceae bolism; filamentous fungi. and Leotiomycetes. Their structure is characterized by numerous hydroxylated non-proteinogenic amino acids. Biosynthetic clusters discovered in the last years contain up to six oxygenases, all of which are involved in amino 1 Introduction acid modifications. Especially, variations in the oxidation Echinocandins are fungal non-ribosomal cyclic hexapep- pattern induced by these enzymes account for a remark- tides with a fatty acid side chain attached to a dihydroxy- able structural diversity among the echinocandins. This ornithine residue. As they are specific noncompetitive review provides an overview of the current knowledge of inhibitors of the β-1,3-glucan synthase involved in fungal echinocandin biosynthesis with a special focus on diver- cell wall biosynthesis, they have a pronounced antifungal sity-inducing oxidation steps. The emergence of metabolic bioactivity. Although natural echinocandins are not of diversity is further discussed on the basis of a comprehen- clinical use due to their toxicity and low solubility, chemi- sive overview of the structurally characterized echinocan- cal derivatives such as caspofungin, anidulafungin, and dins, their producer strains and biosynthetic clusters.
    [Show full text]
  • Description Price NDC CABLE PULSE OX (4083) 0 DERMABOND(DNX12) (SEE MIKE) 0 HO-CEMENTED STEM SZ 16 71316216 10671.26 NECK METHA MOD
    Description Price NDC CABLE PULSE OX (4083) 0 DERMABOND(DNX12) (SEE MIKE) 0 HO-CEMENTED STEM SZ 16 71316216 10671.26 NECK METHA MOD. 130DEG./7.5 L NC077K 8451.29 NECK METHA MOD. 130DEG/7.5 L-R NC079K 8400.06 NEEDLE HOLDER WEBSTER P0405 0 POLYP ETRAP 00711099 1202.32 SET CLEANING BRUSHES 0 TIDISHIELD FRAMES/LENS 9210A-100 0 #1613 VENTILATOR CIR 20.01 #1627 VENTILATOR CIR 21.39 #9 WINDOW ENVELOPE(LAB) 0 * 0 ** 3A ANDROSTANEDIOL GLUCURONIDE 345.81 ** ALKALINE PHOSPHATASE (FRAC) 70.66 ** ALKALINE PHOSPHATASE (FRAC) 99.51 ** CSF3R EXON 14/17 MUTATION 787.47 ** FCM EACH ADDITIONAL MARKER 19.76 ** FECAL ALPHA-1 ANTIRYPSIN 183.16 ** FLOW CYTO INTER/REPT 2 TO 8 MARKERS 115.37 ** TRICYCLIC ANTIDEPRESSANTS QNT UR 227.87 ** URINE PHOSPHORUS ASSAY 70.66 **% DELTA 2 HR 0 **% DELTA 4 HR 0 **% DELTA 6 HR 0 **(RI ANTIBODY WESTERN BLOT ATHENA 246.62 *****UR MICROSCOPIC ONLY 61.69 *****URINALYSIS CANCELLATION NOTICE 0 *****URINALYSIS,BIOCHEM REQUEST 0 *****URINALYSIS,BIOCHEM REQUEST 0 ****2HR URINE CREATININE 70.66 ****CHLAMYDIA PNEUMONIAE AB IGG 79.32 ****HLA TYPING FOR CELIAC DISEASE 0 ****PLATELET AB SERUM 250.95 ****PLATELET PHERESIS LEUKO RED IRRAD 2787.85 ****VMA-SERUM 294.23 ***ANAPLASMA AMP DNA PROBE 469.17 ***BLEEDING TIME 62.02 ***HLA-B27 DNA TYPING 0 ***HSV AB IGM 197.59 ***IGG SERUM 172.72 ***IMMUNOGLOBULIN IGA1 SUBCLASS 57.69 ***IMMUNOGLOBULIN IGA2 SUBCLASS 57.69 ***LYME ANTIGEN DETECTION ELISA 167.67 ***LYME IGM ANTIBODY 204.8 ***MOLD ALLERGEN SCREEN 109.61 ***PATHOLOGY GROSS ONLY 0 **1 HR INCUBATION MIX PROGRESSIVE 89.43 **11 DEOXYCORTISOL
    [Show full text]
  • Lactoferrin, Chitosan and Melaleuca Alternifolia—Natural Products That
    b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 9 (2 0 1 8) 212–219 ht tp://www.bjmicrobiol.com.br/ Review Lactoferrin, chitosan and Melaleuca alternifolia—natural products that show promise in candidiasis treatment ∗ Lorena de Oliveira Felipe , Willer Ferreira da Silva Júnior, Katialaine Corrêa de Araújo, Daniela Leite Fabrino Universidade Federal de São João del-Rei/Campus Alto Paraopeba, Minas Gerais, MG, Brazil a r t i c l e i n f o a b s t r a c t Article history: The evolution of microorganisms resistant to many medicines has become a major chal- Received 18 August 2016 lenge for the scientific community around the world. Motivated by the gravity of such a Accepted 26 May 2017 situation, the World Health Organization released a report in 2014 with the aim of providing Available online 11 November 2017 updated information on this critical scenario. Among the most worrying microorganisms, Associate Editor: Luis Henrique species from the genus Candida have exhibited a high rate of resistance to antifungal drugs. Guimarães Therefore, the objective of this review is to show that the use of natural products (extracts or isolated biomolecules), along with conventional antifungal therapy, can be a very promising Keywords: strategy to overcome microbial multiresistance. Some promising alternatives are essential Candida oils of Melaleuca alternifolia (mainly composed of terpinen-4-ol, a type of monoterpene), lacto- Lactoferrin ferrin (a peptide isolated from milk) and chitosan (a copolymer from chitin).
    [Show full text]
  • A Fresh Look at Echinocandin Dosing
    J Antimicrob Chemother 2018; 73 Suppl 1: i44–i50 doi:10.1093/jac/dkx448 We can do better: a fresh look at echinocandin dosing Justin C. Bader1, Sujata M. Bhavnani1, David R. Andes2 and Paul G. Ambrose1* 1Institute for Clinical Pharmacodynamics (ICPD), Schenectady, NY, USA; 2University of Wisconsin, Madison, WI, USA *Corresponding author. Institute for Clinical Pharmacodynamics (ICPD), 242 Broadway, Schenectady, NY 12305, USA. Tel: !1-518-631-8101; Fax: !1-518-631-8199; E-mail: [email protected] First-line antifungal therapies are limited to azoles, polyenes and echinocandins, the former two of which are associated with high occurrences of severe treatment-emergent adverse events or frequent drug interactions. Among antifungals, echinocandins present a unique value proposition given their lower rates of toxic events as compared with azoles and polyenes. However, with the emergence of echinocandin-resistant Candida species and the fact that a pharmacometric approach to the development of anti-infective agents was not a main- stream practice at the time these agents were developed, we question whether echinocandins are being dosed optimally. This review presents pharmacokinetic/pharmacodynamic (PK/PD) evaluations for approved echino- candins (anidulafungin, caspofungin and micafungin) and rezafungin (previously CD101), an investigational agent. PK/PD-optimized regimens were evaluated to extend the utility of approved echinocandins when treating patients with resistant isolates. Although the benefits of these regimens were apparent, it was also clear that anidulafungin and micafungin, regardless of dosing adjustments, are unlikely to provide therapeutic exposures sufficient to treat highly resistant isolates. Day 1 probabilities of PK/PD target attainment of 5.2% and 85.1%, respectively, were achieved at the C.
    [Show full text]
  • The Impact of Lemongrass, Oregano, and Thyme Essential Oils on Candida Albicans’
    Walden University ScholarWorks Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral Studies Collection 2018 The mpI act of Lemongrass, Oregano, and Thyme Essential Oils on Candida albicans' Virulence Factors Jennifer Marie Eddins Walden University Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations Part of the Alternative and Complementary Medicine Commons, Microbiology Commons, and the Public Health Education and Promotion Commons This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been accepted for inclusion in Walden Dissertations and Doctoral Studies by an authorized administrator of ScholarWorks. For more information, please contact [email protected]. Walden University College of Health Sciences This is to certify that the doctoral dissertation by Jennifer M. Eddins has been found to be complete and satisfactory in all respects, and that any and all revisions required by the review committee have been made. Review Committee Dr. Aimee Ferraro, Committee Chairperson, Public Health Faculty Dr. Angela Prehn, Committee Member, Public Health Faculty Dr. Jagdish Khubchandani, University Reviewer, Public Health Faculty Chief Academic Officer Eric Riedel, Ph.D. Walden University 2018 Abstract The Impact of Lemongrass, Oregano, and Thyme Essential Oils on Candida albicans’ Virulence Factors by Jennifer M. Eddins BS, Colorado State University, 1989 Dissertation Submitted in Partial Fulfillment
    [Show full text]
  • Fd0063e4373375153919749a1d
    Echinocandin Treatment of Pneumocystis Pneumonia in Rodent Models Depletes Cysts Leaving Trophic Burdens That Cannot Transmit the Infection Melanie T. Cushion1,2*, Michael J. Linke2, Alan Ashbaugh1,2, Tom Sesterhenn1,2, Margaret S. Collins1,2, Keeley Lynch1,2, Ronald Brubaker3, Peter D. Walzer1,2 1 College of Medicine, University of Cincinnati, Cincinnati, Ohio, United States of America, 2 Veterans Administration Medical Center, Cincinnati, Ohio, United States of America, 3 Department of Pathology, The Christ Hospital, Cincinnati, Ohio, United States of America Abstract Fungi in the genus Pneumocystis cause pneumonia (PCP) in hosts with debilitated immune systems and are emerging as co- morbidity factors associated with chronic diseases such as COPD. Limited therapeutic choices and poor understanding of the life cycle are a result of the inability of these fungi to grow outside the mammalian lung. Within the alveolar lumen, Pneumocystis spp., appear to have a bi-phasic life cycle consisting of an asexual phase characterized by binary fission of trophic forms and a sexual cycle resulting in formation of cysts, but the life cycle stage that transmits the infection is not known. The cysts, but not the trophic forms, express b -1,3-D-glucan synthetase and contain abundant b -1,3-D-glucan. Here we show that therapeutic and prophylactic treatment of PCP with echinocandins, compounds which inhibit the synthesis of b -1,3-D-glucan, depleted cysts in rodent models of PCP, while sparing the trophic forms which remained in significant numbers. Survival was enhanced in the echincandin treated mice, likely due to the decreased b -1,3-D-glucan content in the lungs of treated mice and rats which coincided with reductions of cyst numbers, and dramatic remodeling of organism morphology.
    [Show full text]
  • ASTELLAS Factsheet 1.Pdf
    Astellas is actively committed to the infectious disease field. Our infectious disease portfolio includes three classes of drugs: AmBisome® (amphotericin B) liposome for injection, CRESEMBA® (isavuconazonium sulfate), and MYCAMINE® (micafungin sodium) for injection. We continue to expand the knowledge base of this therapeutic area and empower physicians to make evidence-based clinical decisions. Our proud history of collaborating with clinical investigators has provided opportunities around the world to study compounds that have the potential to be significant breakthroughs and allows us to generate and publish key information about these advances. In fact, Astellas pioneered the empiric antifungal clinical trial and has performed some of the world’s largest clinical trials in fungal infections. AmBisome® is indicated for the following: • The incidence of some common adverse events was • Empirical therapy for presumed fungal infection in greater in patients taking AmBisome compared to febrile neutropenic patients patients taking Abelcet in the clinical study noted above • Treatment of Cryptococcal Meningitis in HIV-infected including: chest pain, hypocalcemia, hypomagnesemia, patients confusion, headache, and rash • Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to Important Safety Information amphotericin B deoxycholate, or in patients where renal Despite significantly less nephrotoxicity observed at a dose impairment or unacceptable toxicity precludes the use range of 1.5–6.0 mg/kg/day compared to amphotericin B of amphotericin B deoxycholate deoxycholate at a dose range of 0.3–1.2 mg/kg/day in a • Treatment of visceral leishmaniasis; in randomized clinical trial, dose-limiting renal toxicity may still immunocompromised patients with visceral be observed with AmBisome.
    [Show full text]
  • Micafungin in a Nutshell: State of Affairs on the Pharmacological and Clinical Aspects of the Novel Echinocandin
    Drug Evaluation Micafungin in a nutshell: state of affairs on the pharmacological and clinical aspects of the novel echinocandin Micafungin is one of three echinocandin antifungals approved by the US FDA and the European Medicines Agency (EMA). Like all echinocandin antifungals, micafungin inhibits the synthesis of 1,3‑b‑d‑glucan, a main component of the cell wall of many medically important fungi; thus, exerting fungicidal activity against most Candida spp., as well as fungistatic activity against many Aspergillus spp. Micafungin displays linear pharmacokinetics over the therapeutic range with a long half‑life, allowing once‑daily intravenous administration. Steady state serum concentrations are achieved after 3 days. Since therapeutic concentrations of micafungin are achieved after the administration of a standard dose there is no need for a loading dose. Interactions of micafungin with the cytochrome P450 (CYP3A4) system are marginal; and, consequently, no severe drug–drug interactions have been reported so far. Furthermore, micafungin exhibited favorable profiles for tolerability and safety; no dose‑limiting toxicity has been established yet. However, despite its favorable characteristics, these are no unique features among the echinocandins. Nevertheless, micafungin is the only echinocandin that has been approved for the prophylaxis of Candida spp. infections in patients undergoing hematopoietic stem cell transplantation. KEywords: antifungal agents n aspergillosis n candidiasis n dose–response Fedja Farowski†1, relationship n drug administration schedule n drug interactions n lipoproteins Jörg J Vehreschild2, n mycoses n peptides Oliver A Cornely1,3 & Maria JGT Vehreschild1 The incidence of invasive fungal diseases (IFDs) patients with febrile neutropenia (FN), treat- 1Klinikum der Universität zu Köln, has increased, mainly owing to the growing num- ment of esophageal candidiasis, candidemia Klinik I für Innere Medizin, 50924 Köln, ber of immunocompromised patients in recent and other spp.
    [Show full text]
  • Echinocandins As Biotechnological Tools for Treating Candida Auris Infections
    Journal of Fungi Review Echinocandins as Biotechnological Tools for Treating Candida auris Infections 1,2, 1, 1,2 Elizabete de Souza Cândido y , Flávia Affonseca y, Marlon Henrique Cardoso and Octavio Luiz Franco 1,2,* 1 S-Inova Biotech, Programa de Pós Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande 79117900; Brazil; [email protected] (E.d.S.C.); flavia.aff[email protected] (F.A.); [email protected] (M.H.C.) 2 Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília, Brasília 70790160, Brazil * Correspondence: [email protected] These authors equally contributed for this work. y Received: 31 July 2020; Accepted: 9 September 2020; Published: 22 September 2020 Abstract: Candida auris has been reported in the past few years as an invasive fungal pathogen of high interest. Its recent emergence in healthcare-associated infections triggered the efforts of researchers worldwide, seeking additional alternatives to the use of traditional antifungals such as azoles. Lipopeptides, specially the echinocandins, have been reported as an effective approach to control pathogenic fungi. However, despite its efficiency against C. auris, some isolates presented echinocandin resistance. Thus, therapies focused on echinocandins’ synergism with other antifungal drugs were widely explored, representing a novel possibility for the treatment of C. auris infections. Keywords: lipopeptides; echinocandins; Candida auris; infections; antifungal drugs 1. Introduction Candidiasis is one of the most common causes of fungal infection on a global scale and includes both superficial and invasive infections. The major concern is associated with patients in intensive care units (ICU) with high mortality rates. There are several fungal species isolated in the clinical setting responsible for these infections.
    [Show full text]
  • Antimicrobial Treatment of Candidiasis and Aspergillosis No Potential Conflicts of Interest
    2/1/2017 Disclosures Antimicrobial Treatment of Candidiasis and Aspergillosis No potential conflicts of interest. B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Which is the most appropriate initial empirical therapy in a candidemic patient? 3/3 blood cultures are positive for an unidentified yeast……… 1. An echinocandin 2. Liposomal amphotericin 3. Fluconazole 4. Voriconazole 1 2/1/2017 Fluconazole Voriconazole Echinocandin Changing Prevalence of Candidemia (% R) (% R) (% R) C. albicans 0.4% 0.4% 0-0.2% (n=1405) Atlanta Baltimore C. glabrata 1992-1993 2008-2011 1992-1993 2008-2011 8.8% 10.5% 1.2-1.8% (n=571) C. albicans 52% 40% 43% 33% C. tropicalis 1.3% 0.3% 0% (n=318) Non-albicans 48% 60% 58% 67% Candida C. parapsilosis 2.1% 0.2% 0-0.5% (n=565) (Clin Infect Dis 2012; 55: 1352) C. krusei NA 1.3% 0% (n=79) (J Clin Microbiol 2013; Posted online 29 May 2013, doi: 10.1128/JCM.00308-13 ) Fluconazole vs AMB in the Azoles Treatment of Candidemia • 237 patients enrolled with candidemia • Fluconazole (Diflucan®) • Successfully treated (14 days after last positive • Voriconazole (Vfend®) blood culture): • Posaconazole (Noxafil®) – AMB: 81/103 (79 %) – FLU: 72/103 (70%) • Isavuconazole (Cresemba®) • Predominantly C. albicans • Intravascular catheters most frequent source of candidemia • Less toxicity with fluconazole (and PO administration) than with amphotericin B. (N Engl J Med 1994; 331: 1330) 2 2/1/2017 Voriconazole vs Amphotericin Caspofungin vs Amphotericin for followed by Fluconazole
    [Show full text]